Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT3789 in SMARCA4-mutant advanced solid tumors
NCT05639751Phase 1Completed
- Sponsor
- Prelude Therapeutics
- Start
- May 2023
- Primary completion
- Oct 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 5
01
Overview
Phase 1, open-label trial of PRT3789 in solid tumor (advanced stage), metastatic solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Prelude Therapeutics. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events at 3 years and 2 more. Started May 2023; status: completed.
02
Drugs
PRT3789
03
Conditions
solid tumor (advanced stage)metastatic solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05639751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639751.